Auris Medical
Auris Medical is working on medications to prevent
and/or treat certain types of hearing loss. Here's a running chronology
of their progress!
March 2005 - We've been following work on a pill that prevents NIHL when taken prior to
exposure. Now we learn of a medication that claims to
prevent NIHL when taken AFTER exposure. And it may also prevent the
destruction of residual hearing following CI surgery!
June 2006 - Auris Medical
Otoprotective Drug Clinical Trial
February 2007 - Update on Auris
Medical's Otoprotective Medication
February 2007 - Auris
Medical Initiating Clinical Trial with Tinnitus Drug
August 2008 -
Auris Medical reports results of tinnitus drug phase I/II clinical trial
~~~~~~~~~~~~~~~~~~~
Editor: We've been following a product from Sound Pharmaceuticals
that seems to prevent noise induced hearing loss (NIHL) when taken prior
to noise exposure. Now we learn that a new product from Auris Medical
may be effective in preventing NIHL even when taken AFTER exposure to
noise; and it may also prevent the loss of residual hearing following CI
surgery! Here's their recent press release. For more information please
point your browser to http://www.aurismedical.com/seiten_e/03_news_05.htm
~~~~~~~~~~~~~~~~~~~
New data confirms strong otoprotective effect of Auris Medical's
AM-111
New research data presented at the Midwinter Research Meeting of the
Association for Research in Otolaryngology (ARO) in New Orleans
confirmed the strong otoprotective effect of AM-111, Auris Medical's D-JNK
inhibitor for the treatment of acute sensorineural hearing loss. One
poster presented by the Institute for Neuroscience of Montpellier and
Auris Medical showed some first results obtained from an acute acoustic
trauma model with guinea pigs. AM-111 proved to be very effective in
protecting against permanent sensorineural hearing loss even if
administered only after noise exposure (6 kHz pure tone, 120 dB for 30
minutes) and in just one single dose. The therapeutic window was 12
hours. Detailed results shall be published later this year.
In a second poster presented by a research group of the University of
Miami School of Medicine and University Montpellier, AM-111 was shown to
protect against sensorineural hearing loss induced by cochlear implant
electrode insertion. Intracochlear administration of AM-111 for seven
days in guinea pigs proved to be an effective protection against the
progressive component of electrode trauma-induced hearing loss.
The results presented at the ARO research meeting provide further
evidence of the strong otoprotective effects of Auris Medical's AM-111.
The compound is a cell permeable peptide that selectively blocks JNK
MAPK mediated apoptosis of oxidative-stress injured cochlear hair cells
and neurons. Treatment with AM-111 thus allows to protect against
permanent hearing loss induced by exposure to excessive noise, electrode
insertion in cochlear implant surgeries and possibly various other
traumatic incidents as well. Auris Medical intends to start a first
clinical trial with AM-111 within 12 months, subject to regulatory
approval. AM-111 was originally developed by Xigen S.A. and in-licensed
by Auris Medical for the field of ear disorders.
